Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030

Sandoz

31 May 2022 - Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders.

Sandoz today announced the launch of a new global initiative called ‘Act4Biosimilars’ to help address health inequity and inequality worldwide. 

Act4Biosimilars aims to increase patient access to advanced medicines by facilitating greater approvability, accessibility, acceptability and affordability (the 4 A’s) of biosimilars.

Read Sandoz press release

Michael Wonder

Posted by:

Michael Wonder